151 related articles for article (PubMed ID: 21439363)
21. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding.
Karki S; Friscić T; Jones W; Motherwell WD
Mol Pharm; 2007; 4(3):347-54. PubMed ID: 17497885
[TBL] [Abstract][Full Text] [Related]
22. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
[TBL] [Abstract][Full Text] [Related]
23. Near InfraRed Spectroscopy homogeneity evaluation of complex powder blends in a small-scale pharmaceutical preformulation process, a real-life application.
Storme-Paris I; Clarot I; Esposito S; Chaumeil JC; Nicolas A; Brion F; Rieutord A; Chaminade P
Eur J Pharm Biopharm; 2009 May; 72(1):189-98. PubMed ID: 19059338
[TBL] [Abstract][Full Text] [Related]
24. Application of a rapid and integrated analysis system (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry.
Luippold AH; Arnhold T; Jörg W; Krüger B; Süssmuth RD
J Biomol Screen; 2011 Mar; 16(3):370-7. PubMed ID: 21335598
[TBL] [Abstract][Full Text] [Related]
25. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report.
Karanth H; Shenoy VS; Murthy RR
AAPS PharmSciTech; 2006 Oct; 7(4):87. PubMed ID: 17233539
[TBL] [Abstract][Full Text] [Related]
26. Pharmaceutical cocrystallization techniques. Advances and challenges.
Rodrigues M; Baptista B; Lopes JA; Sarraguça MC
Int J Pharm; 2018 Aug; 547(1-2):404-420. PubMed ID: 29890258
[TBL] [Abstract][Full Text] [Related]
27. Effect of powder processing on performance of fenofibrate formulations.
Jain RA; Brito L; Straub JA; Tessier T; Bernstein H
Eur J Pharm Biopharm; 2008 Jun; 69(2):727-34. PubMed ID: 18226885
[TBL] [Abstract][Full Text] [Related]
28. Improved understanding of factors contributing to quantification of anhydrate/hydrate powder mixtures.
Rantanen J; Wikström H; Rhea FE; Taylor LS
Appl Spectrosc; 2005 Jul; 59(7):942-51. PubMed ID: 16053567
[TBL] [Abstract][Full Text] [Related]
29. Continuous powder feeding for pharmaceutical solid dosage form manufacture: a short review.
Blackshields CA; Crean AM
Pharm Dev Technol; 2018 Jul; 23(6):554-560. PubMed ID: 28590824
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel approach towards predicting the milling behaviour of pharmaceutical powders.
Kwan CC; Chen YQ; Ding YL; Papadopoulos DG; Bentham AC; Ghadiri M
Eur J Pharm Sci; 2004 Dec; 23(4-5):327-36. PubMed ID: 15567285
[TBL] [Abstract][Full Text] [Related]
31. Reaction crystallization of pharmaceutical molecular complexes.
Rodríguez-Hornedo N; Nehm SJ; Seefeldt KF; Pagan-Torres Y; Falkiewicz CJ
Mol Pharm; 2006; 3(3):362-7. PubMed ID: 16749868
[TBL] [Abstract][Full Text] [Related]
32. Quantification of Tribocharging of Pharmaceutical Powders in V-Blenders: Experiments, Multiscale Modeling, and Simulations.
Naik S; Hancock B; Abramov Y; Yu W; Rowland M; Huang Z; Chaudhuri B
J Pharm Sci; 2016 Apr; 105(4):1467-77. PubMed ID: 26921122
[TBL] [Abstract][Full Text] [Related]
33. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).
Zhao H; Graf O; Milovic N; Luan X; Bluemel M; Smolny M; Forrer K
J Pharm Sci; 2010 May; 99(5):2279-94. PubMed ID: 20014026
[TBL] [Abstract][Full Text] [Related]
34. Effect of source variation on drug release from HPMC tablets: linear regression modeling for prediction of drug release.
Piriyaprasarth S; Sriamornsak P
Int J Pharm; 2011 Jun; 411(1-2):36-42. PubMed ID: 21420475
[TBL] [Abstract][Full Text] [Related]
35. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
[TBL] [Abstract][Full Text] [Related]
36. The comprehensive profiling of drug substances and pharmaceutical excipients. Preface.
Brittain HG
Profiles Drug Subst Excip Relat Methodol; 2013; 38():xi. PubMed ID: 23668412
[No Abstract] [Full Text] [Related]
37. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
Zhang GG; Law D; Schmitt EA; Qiu Y
Adv Drug Deliv Rev; 2004 Feb; 56(3):371-90. PubMed ID: 14962587
[TBL] [Abstract][Full Text] [Related]
38. Surface responses and desirability functions to determine optimal granulation domains.
Giry K; Viana M; Genty M; Wüthrich P; Chulia D
Drug Dev Ind Pharm; 2010 Sep; 36(9):1016-26. PubMed ID: 20818964
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a high-throughput screening method for the detection of the excipient-mediated precipitation inhibition of poorly soluble drugs.
Petruševska M; Urleb U; Peternel L
Assay Drug Dev Technol; 2013 Mar; 11(2):117-29. PubMed ID: 23116459
[TBL] [Abstract][Full Text] [Related]
40. Blend uniformity end-point determination using near-infrared spectroscopy and multivariate calibration.
Sulub Y; Konigsberger M; Cheney J
J Pharm Biomed Anal; 2011 Jun; 55(3):429-34. PubMed ID: 21398064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
